ANI Pharmaceuticals Inc (ANIP) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with ANIP
Recent news
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
ANIP
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANIP
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIPNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.53
- MACD 12/26/9
- -0.70
- EMA 9 of MACD
- -0.53
- MACD histogram
- -0.16
- SMA 50
- $74.70
- Price below SMA 50
- EMA 50
- $74.74
- Price below EMA 50
- SMA 200
- $78.31
- Price below SMA 200
- EMA 200
- $78.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 3 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
ANIPANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIPShould You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANIPANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANIP
ANI Pharmaceuticals Q2 Earnings Call Highlights
ANI Pharmaceuticals Q2 Earnings Call Highlights
ANIP
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANIP
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANIP
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
ANIP
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANIPNews tone: automated (AI) classification of the article's content, not a price prediction.
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Nikhil Lalwani | President, CEO & Director | 1978 |
| Mr. Stephen P. Carey | Senior VP of Finance & CFO | 1971 |
| Ms. Meredith W. Cook J.D. | Senior VP, General Counsel & Corporate Secretary | 1974 |
| Mr. Christopher K. Mutz | Senior VP & Head of Rare Disease | 1972 |
| Mr. Ori Gutwerg | Senior Vice President of Generics | 1975 |
| Mr. Muthusamy Shanmugam MS R.Ph. | Head of R&D and COO of New Jersey Operations | 1968 |
| Ms. Irina Rivkind Koffler | Vice President of Investor Relations | — |
| Ms. Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease | — |
| Mr. Chad Gassert | Senior Vice President of Corporate Development & Strategy | 1976 |
| Ms. Krista L. Davis | Senior VP & Chief Human Resources Officer | 1973 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 43.53
- MACD 12/26/9
- -0.70
- EMA 9 of MACD
- -0.53
- MACD histogram
- -0.16
- SMA 50
- $74.70
- Price below SMA 50
- EMA 50
- $74.74
- Price below EMA 50
- SMA 200
- $78.31
- Price below SMA 200
- EMA 200
- $78.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $85.00
- Average
- $98.00
- High
- $119.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.2 | -26.4 | +14.0 | |||||||||
| 2022 | -14.3 | -4.8 | -23.8 | +2.9 | +0.3 | -2.8 | +8.6 | +9.2 | -13.1 | +21.0 | +7.6 | +3.6 |
| 2023 | +11.7 | -5.6 | -9.4 | -2.8 | +18.4 | +16.0 | -2.7 | +26.8 | -10.1 | +8.6 | -19.2 | +9.0 |
| 2024 | -2.4 | +19.7 | +2.9 | -2.8 | -2.4 | +0.4 | +3.6 | -0.2 | -5.3 | -3.7 | -1.6 | -4.5 |
| 2025 | +5.8 | +6.9 | +14.5 | +4.1 | -16.9 | +5.4 | -0.3 | +46.3 | -2.7 | +0.5 | -9.8 | -6.5 |
| 2026 | +4.4 | -7.6 | +2.2 | +4.6 | -2.3 | +7.9 | -4.6 | -8.5 | +1.0 | -1.3 |
